The KDIGO Controversies Conference on Therapies Targeting B Cells in Immune-Mediated Kidney Diseases gathered a global multidisciplinary panel of nephrologists, rheumatologists, pathologists, immunologists, cell therapists, and patients to address the therapeutic strategy of targeting of B-cells for the management of autoimmune and immune-mediated kidney diseases. The goal of this KDIGO conference was to review the efficacy and safety of B cell-targeted approaches directed at the underlying drivers of disease and to assess how they supplement or replace existing management paradigms.

Dr. Jürgen Floege (University of Aachen, Germany) and Dr. Brad Rovin (Ohio State University, United States) co-chaired this conference.

PLENARY SESSION RECORDINGS

Click to watch the full playlist on the KDIGO YouTube Channel.  

Introduction and Setting the Tone – Brad Rovin, MD 

Antigen-Specific B Cell Targeting with a Focus on MN – Nicola Tomas

B Cell Depletion for Lupus Nephritis – Anne Davidson

B Cell Therapy & Podocytopathies – Adrian Liew (Singapore)

A Vision of B Cell Targeting for IgAN – Jonathan Barratt (United Kingdom)

Patient Panel 

DEBATE 1 – CD19 CAR T vs CD19+ BCMA Cart T

DEBATE 2, PART 1 – Autologous CAR T vs. Allogenic CAR T

DEBATE 2, PART 2 – Autologous CAR T vs. Allogenic CAR T

DEBATE 3, PART 1 – CAR NK Cells+anti-CD20 vs. Bispecific T/B Engagers

DEBATE 3, PART 2 –

CAR NK Cells+anti-CD20 vs. Bispecific T/B Engagers